Our objective was to confirm that PDAC cells surviving genetic ablation of KRAS retain their tumorigenic capacity, to identify stages of tumor progression when KRAS is essential, and to reveal signaling nodes in the KRAS pathway that are responsible for tumor maintenance. This evidence concerns the gene KRAS and neoplasm.